Donald Trump has announced a proposed 100% tariff on imported branded and patented pharmaceutical drugs, scheduled to take effect on October 1, 2025. In response, Indian pharmaceutical industry officials are evaluating the potential implications for the country’s drug exports to the United States. Many within the sector suggest that India’s significant shipments of generic medications, which constitute the bulk of its pharmaceutical exports to the US, may not fall under the new tariff, as it specifically targets “branded or patented” products. Industry sources indicate that exports of patented and branded drugs from India to the US are currently “negligible.” Furthermore, major Indian pharmaceutical companies maintain operational footprints in the American market. Nevertheless, industry watchers caution that the definitive impact will ultimately be determined by the specific details and “fine print” of the announced tariff.
Source: www.news18.com